Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients
Open Access
- 30 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Abstract
Radiomics offers a non-invasive approach to tumor characterization, yet its application in metastatic cancers is limited by intertumor heterogeneity—variability in radiomic phenotypes across lesions within the same patient. We introduce Measured Intrapatient Radiomic Variability (MIRV), a novel metric quantifying heterogeneity using standard-of-care imaging. Applied to 397 metastatic soft-tissue sarcoma patients from the SARC021 trial, MIRV was calculated from pretreatment CT scans using pairwise Euclidean distance and cosine dissimilarity between lesions. Euclidean distance captures absolute differences in radiomic features, while cosine dissimilarity assesses variation in feature patterns independent of magnitude. Higher MIRV correlated with greater variability in tumor-specific response classification and volumetric response, independent of baseline tumor volume. In a subset with liquid biopsy data, MIRV showed a moderate association with ctDNA positivity, suggesting links to molecular heterogeneity. While MIRV was not prognostic for overall survival in the full cohort, higher MIRV was significantly associated with worse survival in leiomyosarcoma patients (n = 165, p = 0.007, FDR = 0.06). These findings establish MIRV as a biomarker for intertumor heterogeneity, with potential to predict mixed treatment responses and guide personalized therapy in metastatic STS. Future studies should assess its relevance across other tumor types and therapeutic settings.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Radiogenomics: bridging the gap between imaging and genomics for precision oncologyMedcomm, 2024
- Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatmentTranslational Oncology, 2024
- Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stageEuropean Journal of Surgical Oncology, 2022
- Machine learning helps identifying volume-confounding effects in radiomicsPhysica Medica, 2020
- Intratumor and Intertumor Heterogeneity in MelanomaTranslational Oncology, 2017
- Tumour heterogeneity and resistance to cancer therapiesNature Reviews Clinical Oncology, 2017
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2017
- A Comprehensive Survey of Clustering AlgorithmsAnnals of Data Science, 2015
- Correction: Corrigendum: Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approachNature Communications, 2014
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013